BioVie Inc. (NASDAQ:BIVIW – Get Free Report) was the recipient of a large drop in short interest in September. As of September 30th, there was short interest totaling 20,933 shares, a drop of 51.6% from the September 15th total of 43,287 shares. Based on an average trading volume of 15,170 shares, the short-interest ratio is presently 1.4 days.
BioVie Stock Performance
Shares of BIVIW traded up $0.01 during trading hours on Wednesday, reaching $0.26. 6,184 shares of the company’s stock traded hands, compared to its average volume of 55,578. The firm’s 50 day simple moving average is $0.30 and its 200-day simple moving average is $0.33. BioVie has a 12 month low of $0.13 and a 12 month high of $0.79.
BioVie’s lead neurodegenerative disease candidate is bezisterim, also known as NE3107, an orally administered investigational therapy designed to cross the blood-brain barrier and modulate inflammatory signaling.
Further Reading
- Five stocks we like better than BioVie
- High Voltage Returns: Navitas Rewires AI Data Centers
- Quantum BioPharma’s Phase 2 Shows Where Biotech Value Actually Gets Built
- Albertsons Is Betting on a Turnaround—But Will It Pay Off?
- Venezuela’s Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit
Receive News & Ratings for BioVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioVie and related companies with MarketBeat.com's FREE daily email newsletter.
